Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) LT-Debt-to-Total-Asset: 0.02 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03378 Hanx Biopharmaceuticals (Wuhan) Co Ltd HKSE:03378
11 GF Score
Price HK$27.56
! 1 Warning Sign
View Full Analysis

What is Hanx Biopharmaceuticals (Wuhan) Co LT-Debt-to-Total-Asset?

Hanx Biopharmaceuticals (Wuhan) Co HKSE:03378 +6.00% 11 LT-Debt-to-Total-Asset is 0.02 as of Dec. 2025. GuruFocus rates HKSE:03378 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Hanx Biopharmaceuticals (Wuhan) Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.02.

Hanx Biopharmaceuticals (Wuhan) Co's long-term debt to total assets ratio increased from Dec. 2023 (0.02) to Dec. 2025 (0.02). It may suggest that Hanx Biopharmaceuticals (Wuhan) Co is progressively becoming more dependent on debt to grow their business.

Hanx Biopharmaceuticals (Wuhan) Co  (HKSE:03378) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Hanx Biopharmaceuticals (Wuhan) Co LT-Debt-to-Total-Asset Related Terms

Hanx Biopharmaceuticals (Wuhan) Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Hanx Biopharmaceuticals (Wuhan) Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hanx Biopharmaceuticals (Wuhan) Co LT-Debt-to-Total-Asset Chart

Hanx Biopharmaceuticals (Wuhan) Co Annual Data
Trend Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.02 0.02 0.02

Hanx Biopharmaceuticals (Wuhan) Co Semi-Annual Data
Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset 0.02 0.02 0.02
HKSE:03378
11GF Score
Hanx Biopharmaceuticals (Wuhan) Co Ltd HKSE:03378
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hanx Biopharmaceuticals (Wuhan) Co LT-Debt-to-Total-Asset Calculation

Hanx Biopharmaceuticals (Wuhan) Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=24.686/1033.444
=

Hanx Biopharmaceuticals (Wuhan) Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=24.686/1033.444
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.02 mean?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a LT-Debt-to-Total-Asset of 0.02 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors.
Is Hanx Biopharmaceuticals (Wuhan) Co's LT-Debt-to-Total-Asset too high?
Hanx Biopharmaceuticals (Wuhan) Co's current LT-Debt-to-Total-Asset is 0.02. Overall, Hanx Biopharmaceuticals (Wuhan) Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hanx Biopharmaceuticals (Wuhan) Co's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Hanx Biopharmaceuticals (Wuhan) Co's LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. Hanx Biopharmaceuticals (Wuhan) Co's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hanx Biopharmaceuticals (Wuhan) Co stock overvalued right now?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a current LT-Debt-to-Total-Asset of 0.02. The current LT-Debt-to-Total-Asset is 0.02. Hanx Biopharmaceuticals (Wuhan) Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378), the current LT-Debt-to-Total-Asset is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hanx Biopharmaceuticals (Wuhan) Co Business Description

Address No. 1 Jiufeng 1st Road, Building A8, Phase II, Bio-Innovation Park, East Lake New Technology Development Zone, Hubei, Wuhan, CHN
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
11GF Score

Get the complete analysis for HKSE:03378

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$27.56
Price